Sabine Mueller

Head - Clinical Programme

The new DCEz, has appointed the world’s leading paediatric neuro oncologist specializing in DIPG, Dr. Sabine Mueller, as the Head of the Clinical Programme of the DCEz; Sabine joins from UCSF hospital in California, where she was the assistant clinical professor for paediatrics. Sabine is a board-certified neurologist with a research program focused on novel therapies for pediatric brain tumors, including convection enhanced delivery drug pathways.

Sabine has significant experience conducting multi-center trials through established consortia, such as the Children's Oncology Group and the Pacific Pediatric Neuro-Oncology Consortium, which she is co-leading. She also collaborates with the Childhood Cancer Survivor Study for her late effect research. Novel therapy trials involving Sabine have included MTX-110 (Panobinostat), and a DIPG peptide vaccine. Sabine has joined DCEz with one primary aim – to make a measurable difference in outcomes for kids with DIPG, at last.

Translate »